REACH-2: Phase III Second-line Ramucirumab vs Placebo in Advanced Hepatocellular Carcinoma With Elevated Baseline AFP Following First-line Sorafenib

June 1-5, 2018; Chicago, Illinois
Ramucirumab showed a significant survival benefit in patients with advanced HCC and a baseline AFP ≥ 400 mg/mL following previous sorafenib treatment.
Format: Microsoft PowerPoint (.ppt)
File Size: 224 KB
Released: June 8, 2018

Acknowledgements

Jointly provided by Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ACHS Logo

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Amgen
Astellas
AstraZeneca
Celgene Corporation
Eisai
Genentech
Janssen Therapeutics
Merck & Co., Inc.
Seattle Genetics

Related Content

From Clinical Care Options (CCO), download a PDF featuring expert discussion of biomarkers in gastrointestinal cancers

John L. Marshall, MD Released: August 18, 2021

Download this short slideset from Clinical Care Options (CCO) on managed care and specialty pharmacy considerations with CAR T-cell therapy

Craig Freyer, PharmD Zahra Mahmoudjafari, PharmD, BCOP, DPLA Released: August 11, 2021

From Clinical Care Options (CCO), download slides reviewing key CAR T-cell therapy considerations for managed care and specialty pharmacy professionals

Craig Freyer, PharmD Zahra Mahmoudjafari, PharmD, BCOP, DPLA Released: August 4, 2021

Video of a live Clinical Care Options (CCO) webinar on immune checkpoint inhibitors for HCC and other hepatobiliary cancers

Lipika Goyal, MD R. Kate Kelley, MD Amit G. Singal, MD, MS Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: July 27, 2021 Expired: July 26, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue